ArticleNPJ precision oncology2026
Independent somatic TP53 mutations in blood and tumor mimicking Li-Fraumeni syndrome in a 94-year-old man.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Accurately determining the origin of TP53 variants detected in blood is essential as such variants may arise from the constitutional state or clonal hematopoiesis (CH). While paired tumor-blood sequencing is widely used to distinguish somatic from constitutional events, convergent acquisition of identical TP53 hotspot mutations in tumor and blood can obscure variant origin and complicate interpretation. Here we report a 94-year-old patient with the TP53 c.524 G > A (p.Arg175His) pathogenic variant identified in both peripheral blood and tumor tissue, initially raising concern for Li-Fraumeni syndrome (LFS). Given the patient's atypical LFS clinical presentations, multi-tissue confirmatory analysis was performed. Normal bladder tissue and skin biopsy each showed trace mutant signal, and fingernail DNA was negative. These findings support independent somatic acquisition of the same TP53 hotspot mutation in hematopoietic and tumor lineages. This case highlights the importance of multi-tissue confirmatory testing to accurately determine the origin of TP53 variants in cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.